NYSEARCA:IHE

Ishares Us Pharmaceuticals Etf ETF News

Financial Services > Asset Management

Buy IHE

*Your capital is at risk

$90.02

+1.03 (+1.16%)

At Close: Jun 03, 2026

ETFs to Buy on Solid Q1 JNJ Earnings Results

12:56pm, Wednesday, 19'th Apr 2023

Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It topped the revenue estimate as well as lifted the full-year outlook.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

07:42am, Monday, 20'th Mar 2023

Sector ETF report for IHE

IHE: A Top-Heavy Pharma ETF That's More Average Than Outstanding

06:07pm, Thursday, 02'nd Feb 2023

IHE tracks the Dow Jones U.S. Select Pharmaceuticals Total Return Index, which invests solely in U.S. pharmaceutical companies. The fund is top-heavy, investing around 40% in just two companies: Johns

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

07:32am, Tuesday, 17'th Jan 2023

Sector ETF report for IHE

Can Health Care Stocks Outperform Again In 2023?

06:09pm, Wednesday, 11'th Jan 2023

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

Amgen to Buy Horizon Therapeutics: ETFs to Bet On

12:48pm, Tuesday, 13'th Dec 2022

Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from t

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

07:32am, Tuesday, 15'th Nov 2022

Sector ETF report for IHE

Pharma ETFs in Focus Post Q3 Earnings

12:47pm, Wednesday, 09'th Nov 2022

The Q3 earnings picture for the healthcare sector seems solid, with results from companies that have reported so far up 2.1% on 5.8% revenue growth.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

07:32am, Tuesday, 13'th Sep 2022

Sector ETF report for IHE

What The Inflation Reduction Act Means For Drug Prices

01:24am, Friday, 26'th Aug 2022

The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry's long-term financial performance. The legislation caps out-of-pocket costs

JNJ Beats on Q2 Earnings, Cuts View: ETFs in Focus

12:25pm, Wednesday, 20'th Jul 2022

Johnson & Johnson continued its long streak of earnings beat. It outpaced revenue estimates as well but cut its full-year guidance on a strong dollar.